CMMB Stock Summary and Trading Ideas (Chemomab Therapeutics Ltd. - American Depositary Shares | NASDAQ:CMMB)

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol CMMB.

As of January 2, 2026, CMMB stock price climbed to $1.82 with 70,220 million shares trading.

CMMB has a beta of 1.06, meaning it tends to be more sensitive to market movements. CMMB has a correlation of 0.08 to the broad based SPY ETF.

CMMB has a market cap of $34.32 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CMMB traded as high as $21.40 and as low as $1.60.

CMMB has underperformed the market in the last year with a price return of -74.9% while the SPY ETF gained +17.6%. CMMB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.8% and -12.5%, respectively, while the SPY returned +2.7% and +1.9%, respectively.

CMMB support price is $1.52 and resistance is $1.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMMB shares will trade within this expected range on the day.